<< Back To Search

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT04975997
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
This study is testing a new drug called iberdomide, along with two other drugs, to see if it works better than the two drugs that are already being used to treat people with a type of cancer called multiple myeloma. The study is taking place in different hospitals, and the people in the study will be chosen randomly to get either the new drugs or the old ones. The study will also check to make sure the new drugs are safe to use.
Third Opinion AI Generated Synopsis

Trial Summary
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: